New Adult T-Cell Leukemia-Lymphoma Study Findings Have Been Reported by Researchers at Fukuoka University (Cdk9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth In Adult T-cell Leukemia/lymphoma).

Researchers at Fukuoka University in Japan have reported new findings on adult T-cell leukemia-lymphoma (ATL), a hematopoietic malignancy with a poor prognosis that develops in approximately 5% of human T-cell leukemia virus type 1 (HTLV-1) carriers. The researchers investigated the effect of a novel CDK9 selective inhibitor, LY2857785, on ATL-related cell lines in vitro, freshly isolated cells from ATL patients ex vivo, and ATL tumor xenografts in mice. They found that LY2857785 significantly reduced cell viability, induced apoptosis, and suppressed the levels of anti-apoptotic protein MCL-1. The inhibitor also increased autophagy and decreased the growth of ATL tumor xenografts. These findings suggest that LY2857785 has potential as a treatment for ATL. [Extracted from the article]